Posts by W. Taylor Kimberly, MD, PhD
-
Plasma Hypoxanthine Is a Biomarker of Brain Edema After Ischemic Stroke
Hannah J. Irvine, W. Taylor Kimberly, MD, PhD, and colleagues have demonstrated that hypoxanthine, a metabolite linked to hypoxia, is associated with brain edema and is attenuated by glibenclamide therapy in patients with large ischemic stroke. It may prove to be a useful response marker during glibenclamide therapy.
-
Risk Score for Early Brain Injury Predicts 90-Day Outcome of Nontraumatic Subarachnoid Hemorrhage
W. Taylor Kimberly, MD, PhD, chief of the Division of Neurocritical Care, and colleagues have created and validated a risk score based on markers of early brain injury that predicts the 90-day risk of poor functional outcome after nontraumatic subarachnoid hemorrhage.
-
Epileptiform Abnormalities Predict Long-term Outcome After Subacute Hemorrhage
Clinicians in the Department of Neurology at Massachusetts General Hospital found that new or worsening epileptiform abnormalities on continuous EEG have a strong, lasting association with poor functional outcome after nontraumatic subarachnoid hemorrhage, suggesting they may guide therapy.
-
Certain CSF Metabolites May Aid Prognostication After Aneurysmal Subarachnoid Hemorrhage
Using two methods of machine learning, Matthew Koch, MD, Aman Patel, MD, W. Taylor Kimberly, MD, PhD. and colleagues have linked increased cerebrospinal fluid concentrations of three metabolites that alter the nitric oxide pathway to poor outcome after aneurysmal subarachnoid hemorrhage.
-
Taurine May Predict Subarachnoid Hemorrhage Outcomes
Predicting aneurysmal subarachnoid hemorrhage is challenging due to the lack of a biometric marker. Using metabolomic profiling, Massachusetts General Hospital researchers identify taurine as a potential biomarker for predicting stroke in patients.
-
Why Mass General Neurologists Are Animated About Big Data
Neurologists at Massachusetts General Hospital are using big data and machine learning to make better and more informed decisions on patient care.
Biography
W. Taylor Kimberly, MD PhD is a stroke and critical care neurologist in the Department of Neurology. He serves as the Associate Director of the MGH Neuroscience Intensive Care Unit and Associate Chief of the Division of Neurocritical Care and Emergency Neurology.
Clinically, he primarily cares for patients in the Neuroscience ICU as part of an integrated and multi-disciplinary team, coordinating care with Neurosurgery and Neuroendovascular specialists. He sees Neuro ICU patients in follow-up in outpatient clinic as part of the Neurorecovery clinical team. He serves on several hospital-based and national committees that focus on clinical guideline development and care improvement.
Dr. Kimberly's research group is located in the Center for Genomic Medicine (Kimberly Lab), and studies metabolomic and neuroimaging biomarkers of subarachnoid hemorrhage, stroke and cerebral edema. The goal of his research is to identify novel pathways and candidate therapeutic targets for the treatment of acute brain injury. Dr. Kimberly has co-led multi-site, randomized, placebo-controlled trials in the prevention of brain edema, and currently co-leads an international phase 3 trial evaluating the safety and efficacy of intravenous glyburide for the prevention of brain edema after large hemispheric stroke.